Abridge bets ambient AI on doctor-patient talks; $300M Series E at $5.3B

Abridge sells a generative AI platform that ambiently listens to clinician-patient conversations and drafts structured, specialty-specific, billing-ready notes for the EHR.

The medical conversation is healthcare's highest-value data: ambient AI turning it into clinically useful, billable notes will be adopted at enterprise scale.

About $27M raised by mid-2022, then $250M Series D (Feb 2025) and $300M Series E (Jun 2025)

Rao, a UPMC cardiologist and former UPMC Enterprises executive, co-founded Abridge in 2018 after realizing he spent more time on notes than with patients. The company first built a patient-facing app that recorded and summarized medical conversations, then launched an enterprise ambient documentation product in 2022 backed by a $12.5M Series A-1 led by Wittington Ventures.

Abridge scaled from about 100 US health systems at its February 2025 Series D (co-led by Elad Gil and IVP) to 150+ by June. Its Contextual Reasoning Engine drafts billable notes at the point of care and pushes into revenue cycle management; the company was named Best in KLAS for Ambient AI and invested in by CVS Health Ventures and NVIDIA.

In June 2025 Abridge closed a $300M Series E led by Andreessen Horowitz with Khosla Ventures, at a reported $5.3B valuation. It said it would support clinicians across more than 50 million medical conversations that year, in 55 specialties and 28 languages, and claimed up to 60-70% burnout reduction with over 90% of clinicians continuing to use it.

Rao combined first-hand clinical credibility with the same painful workflow his product removes, which made health systems trust and pilot the tool.

Ambient documentation attacks an acute, measurable problem — clinician burnout and billions in administrative cost — so ROI was demonstrable early.

Building billing and coding intelligence directly into the model made the scribe sticky: it stopped being a nice-to-have and became part of how claims get paid.

Landed enterprise logos (UPMC, Inova, and 150+ systems) plus strategic backers like CVS Health Ventures and NVIDIA compounded credibility.

Expanding from notes to the revenue cycle widened the addressable market from documentation to the $1.5T US administrative-spend problem.

Start inside a painful workflow with a founder who lived it; a single documented pain grew into the revenue-cycle layer of an entire industry.

As of June 2025 Abridge was actively scaling: 150+ US health systems, expansion of its platform into revenue cycle management, and hiring across engineering and clinical teams. It remained private with no exit announced; its reported $5.3B valuation made it one of the most valuable healthcare AI startups, with competitors including Ambience Healthcare and Suki.